Human Anti-CD151 Recombinant Antibody (clone 11G5a) (CAT#: FAMAB-1034CQ)

Figure 1 MAB 1A5 binds to CD151 not engaged with integrin α3.

Immunoblot of α3 and CD151 after immunoprecipitation of the tetraspanin from A549 cell lysates (Triton X-100) using non-specific mouse antibody (cIgG) and three distinct antibodies against CD151 (1A5, 8C3, and 11G5a).

Palmer, T. D., Martínez, C. H., Vasquez, C., Hebron, K. E., Jones-Paris, C., Arnold, S. A., ... & Chin, J. L. (2014). Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression. Cancer research, 74(1), 173-187.

Figure 2 mAB 1A5 recognizes the integrin-binding domain of CD151.

Two-color flow cytometry of the CD151 human/mouse substitution mutants was used to evaluate what epitope on CD151 is required for mAB 1A5 binding.

Palmer, T. D., Martínez, C. H., Vasquez, C., Hebron, K. E., Jones-Paris, C., Arnold, S. A., ... & Chin, J. L. (2014). Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression. Cancer research, 74(1), 173-187.

Figure 3 Clustering of CD151 through antibodies specific for the integrin-binding domain inhibits tumor cell motility in vivo.

The inhibition of tumor cell dissemination in the presence or absence of anti-CD151 antibodies (11G5A) was compared with the dissemination in the absence of tumor-targeting antibodies (untreated) or a control IgG.

Palmer, T. D., Martínez, C. H., Vasquez, C., Hebron, K. E., Jones-Paris, C., Arnold, S. A., ... & Chin, J. L. (2014). Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression. Cancer research, 74(1), 173-187.

Figure 4 Immunohistochemical detection of CD151 was performed on two cohorts of patients with prostate cancer.

Micrographs of CD151 immunohistochemistry with mAB 11GA or 1A5 on adjacent benign, adjacent normal, and tumor tissue, human prostate cancer tissue while 1A5 does not. In the primary tumor however, similar to 11G5A, 1A5 positively stains the primary tumor.

Palmer, T. D., Martínez, C. H., Vasquez, C., Hebron, K. E., Jones-Paris, C., Arnold, S. A., ... & Chin, J. L. (2014). Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression. Cancer research, 74(1), 173-187.